Oral Squamous Cell Carcinoma Clinical Trial
Official title:
Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma
Oral cancer represents the sixth most common cancer worldwide whilst in Pakistan it ranks
the second most common cancer in either gender. Histologically, over 90% of oral cancer
lesions are squamous cell carcinomas which are diagnosed on the basis of histopathological
analysis. However, proliferation kinetics and nucleolar status are not clearly delineated by
routine H&E examination; thus making use of various proliferation markers imperative for the
purpose.
Nuclear organizer regions (AgNORs) are associated with proliferative activity and represents
as a diagnostic aid in oral malignancies. Similarly, methyl green pyronin (MGP) stain has
also been valuable as a complement in routine histopathological studies of several
neoplastic entities.
Morphometric techniques offer an opportunity to quantify nuclear changes associated with
malignancy and may provide an objective basis for grading the tumors. The present study is
planned to analyze the morphometric parameters of the MGP stain in oral squamous cell
carcinoma, and in their various histological grades, and to assess if the MGP staining
parameters could give information on the aggressiveness of the malignant lesions of oral
cavity.
Sections from thirty cases of squamous cell carcinoma along with thirty cases of normal oral
mucosa will be evaluated for methyl green pyronin (MGP) and AgNOR staining. Morphometric
analysis of various MGP staining and AgNOR parameters would be performed using micrometer.
Statistical analysis of the results will be carried out using SPSS. Quantitative variables
will be expressed as mean ± Standard Deviation. Frequencies and percentages will be given
for qualitative variables.
It is hypothesized that oral squamous cell carcinoma will exhibit significantly higher MGP
staining and AgNOR staining parameters than normal mucosa of the oral cavity.
Oral cancer, a major global health problem holds the sixth position worldwide with a marked
variation in its geographic distribution. It is ranked as the third most frequent cancer in
the developing world after stomach and cervical cancers. Amongst oral cancers, oral squamous
cell carcinoma accounts for over 90% of the cases.
Out of the developing counties, Indo-Pak subcontinent amounts to one third of the global
oral cancer burden. Carcinoma of the oral cavity in Pakistan, one of the high-risk countries
is the second most frequent cancer in either gender. With differential distribution among
sub-populations, it represents 8.8% of all reported cancer cases. The most predominant risk
factors include tobacco smoking, betel chewing and alcohol.
Screening and specific diagnostic tools are two innovative approaches for early detection of
oral cancer. Conventional oral examination and clinical evaluation remains the foundation of
screening approaches whereas surgical biopsy followed by histological analysis is attributed
to be the gold standard for diagnosing malignant oral lesions. Furthermore, some adjunctive
techniques may contribute to the diagnosis of oral cancer. Of these vital staining, DNA
analysis, chemiluminescence, tissue fluorescence, light-based detection systems and
biomarkers are now on the forefront.
Biomarkers have been valuable in revealing additional information about tumor pathology,
including the inactivation of tumor suppressor genes, angiogenesis, apoptosis and cell
proliferation. Aberrations in proliferation kinetics are the most imperative factor during
tumor progression. Three main categories of cell proliferation markers include growth
fraction markers like Ki67, cycle-specific markers like PCNA(Proliferating Cellular Nuclear
Antigen), and cell cycle time markers like AgNOR. During malignancy, proliferation and
protein synthesis is mainly controlled by the nucleus.
Nucleolar Organizer Regions (NORs) are loops of DNA on the short arms of acrocentric
chromosomes that presumably are associated with cell proliferation. Some of the NOR
associated proteins are argyrophilic and can be demonstrated as black dots by the silver
staining technique and the structures thus demonstrated are known as AgNORs. The AgNOR
quantitative parameters provide information about the velocity of cell proliferation during
cell cycle. Neoplastic progression is affected more by the rate of cell proliferation,
rather than the proliferative activity per se.
Although AgNOR staining and AgNOR quantification are valuable methods in histopathological
evaluation of malignancies, certain limitations have also been associated with this
technique. Such AgNOR associated shortcomings include nucleolar affinity for silver stain
obscuring the individual AgNORs in cases of intense staining, overlapping of variable degree
between high and low grade tumors, difficulty in discerning doublets or clusters by light
microscopy, misinterpreted stain deposition as proliferative activity along with some
technical problems of staining and fixation.
Methyl Green Pyronin (MGP) stain is a differential stain used for selective staining of DNA
and RNA. Methyl green binds specifically to deoxyribonucleic acid (DNA), staining nuclei
green, while pyronin is specific for ribonucleic acid (RNA), staining nucleoli red. Methyl
green pyronin stain has also been used to distinguish between proliferating and
dedifferentiated non-proliferating cell nuclei. Similarly to assess the degradation of DNA
in thyroid follicular epithelial cells, this stain has also proven to be useful.
Morphometry has been a significant advancement in delineating sequence of events responsible
for cancer progression. Variations in nuclear and cellular size and shape have greater
implications in the assessment of neoplastic lesions. Methyl Green Pyronin (MGP) stain has
been attracting attention in the recent times as it has been used to evaluate various
nuclear morphometric parameters in breast neoplasms. By using methyl green-pyronin staining,
not only the inadequacies associated with AgNOR staining can be lessened but also the
morphometric parameters for evaluating changes in the nucleus and nucleolus during
carcinogenesis can be accomplished.
So far AgNOR staining appears to be a useful diagnostic tool in oral squamous cell carcinoma
for examination of nucleolar structure and variations in nucleolar activity. On the other
hand, MGP staining has been used in assessing the cancerous lesions of breast and thyroid
gland and recently has been extended to oral lesions. However, no studies have been
undertaken yet to evaluate and compare the morphometric parameters using these two stains
within normal oral epithelium and oral squamous cell carcinoma. Similarly, very few studies
have been undertaken regarding application of methyl green pyronin stain in oral
pathologies.
Hence the current study has been planned to evaluate the morphometric parameters among
normal oral epithelium and oral squamous cell carcinoma using methyl green pyronin staining;
moreover these findings will also be compared with those of AgNOR staining. In this current
scenario, methyl green pyronin staining and morphometric analysis may go hand in hand to
provide a better diagnosis and early detection of oral cancer.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04543266 -
Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning
|
||
Not yet recruiting |
NCT06438939 -
NBI for Early Diagnosis of OPMD/OSCC
|
N/A | |
Recruiting |
NCT05024383 -
Dissecting the Heterogeneity of Oral Cancer Pain
|
N/A | |
Recruiting |
NCT06031337 -
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
|
||
Not yet recruiting |
NCT06174428 -
Validity of Viome's Oral/Throat Cancer Test
|
||
Recruiting |
NCT05098119 -
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
|
Phase 2 | |
Recruiting |
NCT05069857 -
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
|
Phase 2 | |
Not yet recruiting |
NCT03619304 -
Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line
|
N/A | |
Active, not recruiting |
NCT01772706 -
Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05893888 -
Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05125055 -
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06055868 -
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
|
||
Not yet recruiting |
NCT06130007 -
A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.
|
Phase 2 | |
Recruiting |
NCT05798793 -
Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT02739204 -
Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT05708209 -
The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124
|
||
Recruiting |
NCT05862168 -
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma :A Single-arm, Prospective, Phase II Trial
|
Phase 2 | |
Recruiting |
NCT05451303 -
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
|
||
Recruiting |
NCT05902455 -
Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
|
||
Not yet recruiting |
NCT05803915 -
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
|
Phase 2 |